Caris Chromoseq Data Collection
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Caris Science, Inc.
- Study ID
- NCT07680868
- Status
- Recruiting
Conditions
- Acute Myeloid Leukemia (AML)
- Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases
- Myelodysplatic Syndromes
- Myeloproliferative Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Caris Chromoseq — DIAGNOSTIC_TESTThe Caris Chromoseq assay is designed to provide whole genome profiling of hematologic malignancies in the human genome. Various internal studies have been performed that validate the performance of these genetic alterations including SNVs, CNAs, INDELs, and SVs in AML, MDS, and MPN.
Study Details
The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.
Key Dates
- Start date
- Jul 31, 2026
- Status verified
- Jun 2026
- Primary completion
- Jul 31, 2029
- Completion
- Jul 31, 2029
Study Design
- Enrollment
- 300 participants (estimated)
Arms
- Arm: AML, MDS and/or MPNThe study will include approximately 300 subjects in the United States with either AML, MDS and/or MPN who receive the Caris Chromoseq assay who also undergo standard institutional directed conventional cytogenetic analysis.
Primary Outcome Measure
Caris Chromoseq vs Conventional Testing [ Time Frame: 2 years ]
Central Contacts
- Mary Baker602-571-2771
- Harshita Mittal617-862-1263
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Caris Life Sciences | Phoenix | Arizona | 85040 |
Find similar trials in Phoenix, AZ
By research site
Related Studies
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)Recruiting · Center for International Blood and Marrow Transplant Research · Birmingham, Alabama
- Project: Every Child for Younger Patients With CancerRecruiting · Children's Oncology Group · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPHASE3 · Recruiting · Kura Oncology, Inc. · Gilbert, Arizona